Our systematic review on the effi cacy and safety of a fixed-dose combination of indacaterol and glycopyrronium (QVA149) for the treatment of COPD is publishing in this issue of CHEST (see page 309). 1 In this study, we assessed this combination with its monocomponents (glycopyrronium and indacaterol) and tiotropium for the treatment of moderate to severe COPD. Th e results showed a superiority of inhaled QVA149 in terms of effi cacy compared with glycopyrronium and with the current standard of care tiotropium. However, it was not possible to perform a pooled analysis of data comparing QVA149 vs indacaterol because we found only one trial with this comparison. 2 Interestingly, a few days aft er our article published Online First, a new study evaluating the effi cacy and safety of QVA149 against indacaterol alone was published. 3 Because this study met all the inclusion criteria of our review, its data could be analyzed together with the only study that we found 2 and, thereby, expand the results. Th e studies together included a total of 1,399 patients with moderate to severe COPD with a treatment duration of 24 weeks 2 and 12 weeks. 3 Data from both trials indicated that QVA149 was associated with a signifi cant increase in trough FEV 1 at day 1 (mean diff erence, 0.08 L; 95% CI, 0.04-0.12 L; P 5 .0001; I 2 5 0%) and at week 12 (mean diff erence, 0.08 L; 95% CI, 0.04-0.12 L; P 5 .0001; I 2 5 0%) compared with indacaterol monotherapy. Additionally, the combination showed an 11% greater likelihood of experiencing a minimal clinically important diff erence in transitional dyspnea index ( Ն 1 point) with a number needed to benefi t of 11. Although a higher percentage of patients taking QVA149 achieved a minimal clinically important diff erence in St. George's Respiratory Questionnaire score ( Ն 4 units of total score) vs patients taking indacaterol alone, the diff erence was not statistically signifi cant (relative risk, 1.07; 95% CI, 0.98-1.17; P 5 .15; I 2 5 55%). Finally, the overall incidence of adverse events was similar across both treatment groups. Th us, this update of our review confi rms the benefi ts and safety of combined bronchodilator therapy compared not only with glycopyrronium or tiotropium monotherapy but also with indacaterol. References 1. Rodrigo GJ , Plaza V . Effi cacy and safety of a fi xed-dose combination of indacaterol and glycopyrronium for the treatment of COPD: a systematic review .
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